enoxaparin (XRP4563)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hip Fractures
Conditions
Hip Fractures
Trial Timeline
Jul 1, 2006 → Mar 1, 2007
NCT ID
NCT00685958About enoxaparin (XRP4563)
enoxaparin (XRP4563) is a phase 3 stage product being developed by Sanofi for Hip Fractures. The current trial status is completed. This product is registered under clinical trial identifier NCT00685958. Target conditions include Hip Fractures.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00685958 | Phase 3 | Completed |
Competing Products
12 competing products in Hip Fractures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK5211 + Placebo | Viking Therapeutics | Phase 2 | 47 |
| Teriparatide + Placebo | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Zoledronic Acid 5Mg/Bag 100Ml Inj + sodium chloride | Roche | Approved | 85 |
| Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC | Amgen | Phase 3 | 76 |
| rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2/3 | 64 |
| rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| InductOs | Pfizer | Approved | 84 |
| rhBMP-2/CPM | Pfizer | Phase 1 | 32 |
| rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| Tranexamic Acid plus standard of care | Pfizer | Approved | 84 |
| CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 | Pfizer | Phase 2 | 51 |